Related Experiment Video
Updated: May 20, 2026
06:28
E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Randomized Polypill crossover trial in people aged 50 and over
David S Wald1, Joan K Morris, Nicholas J Wald
1Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Plos One
|July 21, 2012
Summary
A Polypill significantly reduced blood pressure and LDL cholesterol in individuals over 50, matching predicted outcomes. These findings suggest potential for preventing cardiovascular disease events like heart attacks and strokes.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Cardiovascular disease (CVD) prevention is a major public health concern.
- A polypill, combining multiple medications, is proposed for primary CVD prevention in at-risk individuals.
- The efficacy of polypills in reducing blood pressure and cholesterol requires further clinical validation.
Purpose of the Study:
- To evaluate the efficacy of a polypill in reducing blood pressure and LDL cholesterol in individuals aged 50 and above.
- To compare the observed reductions with predicted values based on individual drug effects.
- To assess the polypill's potential for primary prevention of cardiovascular disease.
Main Methods:
- A randomized, double-blind, placebo-controlled crossover trial was conducted.
- Participants (aged 50+) without prior CVD history received a polypill (amlodipine, losartan, hydrochlorothiazide, simvastatin) or placebo for 12 weeks each.
- Mean differences in blood pressure and LDL cholesterol were determined and compared to predicted values.
Main Results:
- The polypill significantly reduced systolic blood pressure by 17.9 mmHg (12%) and diastolic blood pressure by 9.8 mmHg (11%).
- LDL cholesterol was reduced by 1.4 mmol/L (39%) with polypill use.
- Observed reductions closely matched predicted values, validating the study's methodology.
Conclusions:
- The polypill effectively achieved predicted reductions in blood pressure and LDL cholesterol.
- Sustained reductions of this magnitude are expected to substantially decrease the incidence of heart attacks and strokes.
- The polypill represents a promising strategy for the primary prevention of cardiovascular disease.
Related Concept Videos
01:16Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...